Campbell & CO Investment Adviser LLC
Position in ABUS — Arbutus Biopharma Corp
CIK 1353570
BALTIMORE, MD
Position in ABUS
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$1,106,563
+$641,209 QoQ
Shares Held
230,534
+122.9% QoQ
Ownership
0.117%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#51
of 175 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABUS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Campbell & CO Investment Adviser LLC holds $72,173,828 across 47 Biotechnology names. ABUS ranks #21 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,899 | $6,172,422 | |
| 2 | CRSP |
CRISPR Therapeutics AG
|
107,529 | $5,864,631 | |
| 3 | CYTK |
Cytokinetics Inc
|
65,978 | $5,620,665 | |
| 4 | INSM |
INSMED Inc
|
43,856 | $4,675,926 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
49,632 | $3,935,321 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
44,702 | $3,498,825 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
11,183 | $3,366,418 | |
| 8 | RPRX |
Royalty Pharma plc
|
52,688 | $2,954,216 |
All Filings in ABUS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,106,563 | 230,534 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $465,354 | 103,412 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $544,073 | 113,113 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $332,713 | 73,285 | Shares | Sole | 2025-10-28 | |
| No filing history on record for this holder in this stock. | ||||||